ANA S. CVETANOVIC^1,2,*, MATTEO LAMBERTINI^3,4, KEVIN PUNIE⁵, GORANA G. MATOVINA BRKO⁶, NIKOLA D. ZIVKOVIC^7,8, MAJA J. POPOVIC^6,9, MARIJANA M. MILOVIC KOVACEVIC¹⁰, LAZAR S. POPOVIC^6,9

Oncology Research, Vol.32, No.8, pp. 1309-1322, 2024, DOI:10.32604/or.2024.049743

Abstract Oncofertility is an extremely significant topic that is increasingly being discussed owing to increased evidence indicating that fertility preservation does not affect the treatment outcomes of patients with cancer but significantly contributes to preserving life quality. The effect of chemotherapy can range from minimal effects to complete ovarian atrophy. Limited data are available on the effects of monoclonal antibodies and targeted therapies on the ovaries and fertility. Temporary ovarian suppression by administering a gonadotropin-releasing hormone agonist (GnRHa) during chemotherapy decreases the gonadotoxic effect of chemotherapy, thereby diminishing the chance of developing premature ovarian insufficiency (POI).… More > Graphic Abstract

Romaissa Kebache¹, Abdelkader Laouid^1,*, Ahcene Bounceur², Mostefa Kara^1,3, Konstantinos Karampidis⁴, Giorgos Papadourakis⁴, Mohammad Hammoudeh²

Computer Systems Science and Engineering, Vol.48, No.4, pp. 1055-1072, 2024, DOI:10.32604/csse.2024.048738

Abstract Internet cloud services come at a price, especially when they provide top-tier security measures. The cost incurred by cloud utilization is directly proportional to the storage requirements. Companies are always looking to increase profits and reduce costs while preserving the security of their data by encrypting them. One of the offered solutions is to find an efficient encryption method that can store data in a much smaller space than traditional encryption techniques. This article introduces a novel encryption approach centered on consolidating information into a single ciphertext by implementing Multi-Key Embedded Encryption (MKEE). The effectiveness… More >

Manal El-Hamamsy^*, Hesham Elwakil^†, Amr S. Saad^†, May A. Shawki^*

Oncology Research, Vol.24, No.6, pp. 521-528, 2016, DOI:10.3727/096504016X14719078133528

Abstract Statins have been reported to have a potential radiosensitizing effect that has not been evaluated in clinical trials. The aim of this study was to evaluate the efficacy and safety of simvastatin in addition to whole-brain radiation therapy (WBRT) in patients with brain metastases (BM). A prospective randomized, controlled, open-label pilot study was conducted on 50 Egyptian patients with BM who were randomly assigned to receive 30-Gy WBRT (control group: 25 patients) or 30 Gy WBRT+ simvastatin 80 mg/day for the WBRT period (simvastatin group: 25 patients). The primary outcome was radiological response at 4… More >

Abdullah A. Alharbi¹, Ahmad Y. Alqassim^1,*, Mohammed A. Muaddi¹, Najat H. Aldubayyan¹, Rana I. Abuhadi¹, Futon A. Akoor¹, Sarah J. Mobarki¹, Imtenan A. Oberi¹, Ghaidaa H. Alharbi¹, Yara Ajeebi¹, Adnan M. Alkhayat², Hafiz Malhan³, Mohammed Bakkar⁴, Anwar M. Makeen¹

International Journal of Mental Health Promotion, Vol.26, No.5, pp. 351-359, 2024, DOI:10.32604/ijmhp.2024.047219

Abstract Sickle Cell Anemia (SCA) is a prevalent genetic condition in Saudi Arabia, particularly in the Jazan region. The study’s purpose was to assess the prevalence of de-pression among individuals with SCA in this area and to identify the factors associated with this condition. The study involved 391 adult participants, all patients in the hematology center of Prince Mohammed bin Nasser Hospital (PMNH). Data was collected through an anonymous interview questionnaire–the Arabic version of the Patient Health Questionnaire-9 (PHQ-9)–between March–May 2022. The questionnaire covered socio-demographic information and variables related to the participant’s SCA history, such as… More >

Yue-shen Wang^*1, Jing Tian^†1, Yong Han^†, Shu-mei Han^†, Sheng-bin Shi^†

Oncology Research, Vol.24, No.2, pp. 129-135, 2016, DOI:10.3727/096504016X14618564639213

Abstract We evaluated the efficacy and feasibility of the combination of gemcitabine plus vinorelbine in patients with platinum-based chemotherapy-refractory esophageal cancer. We enrolled 35 patients who received gemcitabine plus vinorelbine as second-line treatment after platinum-based chemotherapy failure between May 2009 and April 2012. Dosage: gemcitabine 1,000 mg/m² plus vinorelbine 25 mg/m² ; all drugs were administered on days 1 and 8 of a 21-day cycle, and this was continued until failure or unacceptable toxicity. A total of 125 cycles of treatment were administered, and all patients received at least two cycles of treatment (two to five cycles;… More >

Annie Im, Ali Amjad, Mounzer Agha, Anastasios Raptis, Jing-Zhou Hou, Rafic Farah, Seah Lim, Alison Sehgal, Kathleen A. Dorritie, Robert L. Redner, Brian McLaughlin, Yongli Shuai, Shrina Duggal, Michael Boyiadzis

Oncology Research, Vol.24, No.2, pp. 73-80, 2016, DOI:10.3727/096504016X14586627440156

Abstract Relapsed acute myeloid leukemia (AML) represents a major therapeutic challenge. Achieving complete remission (CR) with salvage chemotherapy is the first goal of therapy for relapsed AML. However, there is no standard salvage chemotherapy. The current study evaluated outcomes and prognostic factors for achievement of CR in 91 AML patients in first relapse who were treated with the mitoxantrone–etoposide combination regimen. The overall response rate (CR and CRi) was 25%. Factors that were associated with a lower rate of CR included older age, shorter duration of first CR, low hemoglobin, and low platelet count. The median… More >

Kazuyoshi Kawakami^*, Takashi Yokokawa^*, Kazuo Kobayashi^*, Takahito Sugisaki^*, Kenichi Suzuki^*, Mitsukuni Suenaga^†, Kensei Yamaguchi^†, Ayaka Inoue^‡, Yoshiaki Machida^‡, Toshiharu Yamaguchi^†, Toshihiro Hama^*

Oncology Research, Vol.25, No.9, pp. 1625-1631, 2017, DOI:10.3727/096504017X15012905098071

Abstract Adherence has become an important issue in modern oncology treatment. Most studies have included heterogeneous target tumor types, regimens, and therapy settings. Our study focused on capecitabine during capecitabine plus oxaliplatin (XELOX) treatment as an adjuvant therapy for colorectal cancer. The main aims of this study were to evaluate real-life adherence to capecitabine and to investigate candidate factors that might decrease adherence. We studied 338 consecutive patients who received XELOX treatment between December 1, 2011, and April 30, 2015, at the Cancer Institute Hospital of the Japanese Foundation for Cancer Research. Our study assessed adherence… More >

Baohong Yang^*1, Aiying Qin^†1, Kongyuan Zhang^‡, Haipeng Ren^*, Shuzhen Liu^*, Xiaolei Liu^§, Xiangpo Pan^¶, Guohua Yu^*

Oncology Research, Vol.25, No.9, pp. 1601-1606, 2017, DOI:10.3727/096504017X14928634401178

Abstract Epithelial growth factor receptor (EGFR) mutations are present in 10%–26% of non-small cell lung cancer (NSCLC) tumors and are associated with the response to tyrosine kinase inhibitors (TKIs). This study aimed to detect and quantify the presence of circulating tumor cells (CTCs) in EGFR-mutant NSCLC patients and investigate their possible role in providing prognostic information. Enrolled patients received erlotinib (150 mg) or gefitinib (250 mg) orally once daily as the first-line treatment. Serial blood samples were taken at baseline (CTC-d0) and on day 28 (CTC-d28) following the initiation of erlotinib/gefitinib for detection of CTCs using… More >

Valentina K. Todorova^*, Issam Makhoul^†, Ishwori Dhakal^‡, Jeanne Wei^§, Annjanette Stone^¶, Weleetka Carter^¶, Aaron Owen^*, V. Suzanne Klimberg^*

Oncology Research, Vol.25, No.8, pp. 1223-1229, 2017, DOI:10.3727/096504017X14876245096439

Abstract Doxorubicin (DOX) is a commonly used antineoplastic agent for the treatment of various malignancies, and its use is associated with unpredictable cardiotoxicity. Susceptibility to DOX cardiotoxicity is largely patient dependent, suggesting genetic predisposition. We have previously found that individual sensitivity to DOX cardiotoxicity was associated with differential expression of genes implicated in inflammatory response and immune trafficking, which was consistent with the increasing number of reports highlighting the important role of human leukocyte antigen (HLA) complex polymorphism in hypersensitivity to drug toxicity. This pilot study aimed to investigate DNA from patients treated with DOX-based chemotherapy… More >

Cheng-Jen Ma^*†‡, Ching-Wen Huang^*‡§, Yung-Sung Yeh^*†¶, Hsiang-Lin Tsai^*§#**, Huang-Ming Hu^††‡‡, I-Chen Wu^††‡‡, Tian-Lu Cheng^§§¶¶, Jaw-Yuan Wang^{*†‡§**¶¶}

Oncology Research, Vol.25, No.5, pp. 673-679, 2017, DOI:10.3727/97818823455816X14786040691928

Abstract We analyzed the results of previously treated patients with metastatic colorectal cancer (mCRC) who received regorafenib plus FOLFIRI with the irinotecan dose escalation on the basis of uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) genotyping. Thirteen patients with previously treated mCRC were subjected to UGT1A1 genotyping between October 2013 and June 2015 and were administered regorafenib plus FOLFIRI with irinotecan dose escalation. Patients with UGT1A1*1/*1 and *1/*28 genotypes were administered 180 mg/m² of irinotecan, whereas those with the UGT1A1*28/*28 genotype were administered 120 mg/m2 of irinotecan. For all patients, the irinotecan dose was increased by 30 mg/m2 every… More >